ALKS - Alkermes plc
| Previous Close | 18.58 |
| Open | 18.43 |
| Bid | 18.33 x 800 |
| Ask | 18.35 x 900 |
| Day's Range | 18.12 - 18.60 |
| 52 Week Range | 17.11 - 37.75 |
| Volume | 453,219 |
| Avg. Volume | 1,630,587 |
| Market Cap | 2.882B |
| Beta (5Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings Date | Feb 11, 2020 - Feb 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.55 |
- Zacks
Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Alkermes (ALKS) closed at $19.99, marking a -0.05% move from the previous day.
- Insider Monkey
Hedge Fund Favorites vs. Alkermes Plc (ALKS) In 2019
2018's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the […]
- Simply Wall St.
Does Alkermes plc (NASDAQ:ALKS) Have A High Beta?
If you own shares in Alkermes plc (NASDAQ:ALKS) then it's worth thinking about how it contributes to the volatility of...
- Zacks
Alkermes (ALKS) Gains As Market Dips: What You Should Know
Alkermes (ALKS) closed the most recent trading day at $19.52, moving +1.61% from the previous trading session.
- PR Newswire
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2020 at 9:00 a.m. PT (12:00 p.m. ET/5:00 p.m. GMT) from the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 9:30 a.m. PT (12:30 p.m. ET/5:30 p.m. GMT).The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
- Zacks
LGND vs. ALKS: Which Stock Is the Better Value Option?
LGND vs. ALKS: Which Stock Is the Better Value Option?
- Zacks
Alnylam Stock Up More Than 61% YTD on Pipeline Progress
Shares of Alnylam (ALNY) rise on significant pipeline progress.
- Zacks
Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA
Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.
- Zacks
Seattle Genetics Submits NDA to FDA for Tucatinib Combo
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
- Zacks
All You Need to Know About Alkermes (ALKS) Rating Upgrade to Strong Buy
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
- Zacks
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
- Zacks
5 Losing Stocks From 2019 to Rebound Next Year
The positive sentiment witnessed by Wall Street in 2019 might be prevalent in 2020 as well owing to multiple tailwinds.
- Zacks
Alnylam's Kidney Disease Drug Succeeds in Late Stage Study
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
- Zacks
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
- Zacks
Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
- Zacks
The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora
The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora
- GuruFocus.com
5 Health Care Stocks Gurus Are Buying
Tandem Diabetes Care tops the list Continue reading...
- Zacks
Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
- Zacks
These 5 Loser Stocks of 2019 Could be Big Winners in 2020
As the momentum in the equity markets is expected to stay on firm-footing in 2020, these five stocks that failed to stand out in 2019 have a chance to outperform next year.
- Zacks
Biogen's Gosuranemab Fails in Phase II Brain Disorder Study
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.
- Zacks
Momenta Pharmaceuticals (MNTA) Catches Eye: Stock Jumps 7.1%
Momenta Pharmaceuticals (MNTA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
